Bio-Rad Laboratories (BIO) stock is soaring 6.06% in pre-market trading on Friday, following the release of its first-quarter 2025 earnings report that significantly exceeded analyst expectations. The company reported adjusted earnings of $2.54 per share, surpassing the mean expectation of $1.81 per share from seven analysts.
Despite a 4.2% year-over-year decline in revenue to $585.40 million, Bio-Rad still managed to outperform analyst predictions of $573.26 million. The company's Clinical Diagnostics Group showed resilience amid macroeconomic challenges, while the Life Science segment faced some headwinds, particularly in academia and biopharma research.
However, investors seem to be focusing on the positive aspects of the report, including the company's strong free cash flow of $96 million, up from $30 million in Q1 2024. Bio-Rad's innovative product launches and the upcoming acquisition of Stilla Technology are also likely contributing to investor optimism. The company has adjusted its 2025 guidance, now expecting non-GAAP, currency-neutral revenue to range from a decline of 1% to growth of 1.5%, reflecting ongoing market uncertainties.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.